Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-078004
Filing Date
2025-05-27
Accepted
2025-05-27 19:44:16
Documents
1
Period of Report
2025-05-15

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 3975
  Complete submission text file 0000950170-25-078004.txt   6285
Mailing Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301
Business Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301 (720) 307-2892
OnKure Therapeutics, Inc. (Issuer) CIK: 0001637715 (see all company filings)

EIN.: 472309515 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 420 LEXINGTON AVENUE, SUITE 2626 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE, SUITE 2626 NEW YORK NY 10170 212-299-4777
ACORN BIOVENTURES 2, L.P. (Reporting) CIK: 0001876405 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-40315 | Film No.: 25990503

Mailing Address 420 LEXINGTON AVENUE, SUITE 2626 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE, SUITE 2626 NEW YORK NY 10170 212-299-4777
Acorn Capital Advisors GP 2, LLC (Reporting) CIK: 0002070458 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-40315 | Film No.: 25990502